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Introduction
Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive fibrosing interstitial 
pneumonia with poor diagnosis and a median survival of 2–3 years from initial diagnosis (1, 2). The 
cellular inflammation drives the fibrotic response in lung and plays a major role in IPF pathogenesis 
(3). Inflammatory cells (majorly, type 2 alveolar epithelial cells) release TGF-β, the key mediator of 
pulmonary fibrosis, that regulates several profibrotic cytokines/chemokines, their receptors, recep-
tor subunits, and growth factors inducing process of epithelial–mesenchymal transition (EMT) 
(3, 4). Among the pro-inflammatory and profibrotic cytokines involved in IPF pathogenesis, 
interleukin (IL)-1 (4), IL-1β (5), IL-4, IL-5 (6), IL-6Rα (4), angiogenic IL-8/CXCL-8 (7), IL-13, 
its receptor IL-13 Rα2 (8), and IL-33 (9) have been implicated in accelerated inflammation and 
irreversible damage to lung architecture with loss of alveolar-capillary barrier basal membrane 
leading to persistent fibrosis. Genes encoding these factors exhibit nucleotide variation that could 
affect the severity of immune/inflammatory reactions and extent of any subsequent dysregulated 
fibroproliferative activity in disease development. Furthermore, variants in mucin-encoding genes 
(10–13) and in genes for pathogen-associated molecular patterns (PAMPs) receptors of innate 
immunity known as toll-like receptors (TLRs) (14, 15) have been also implicated in IPF immu-
nopathogenesis and related to rapid progression of the disease. Investigations of these “candidate” 
gene variant(s) e.g., in case-control association studies may, therefore, provide novel insight into 
underlying mechanism of IPF susceptibility/disease outcome and, further, may aid to develop novel 
diagnostic approaches and eventually therapeutic interventions based on genetic information (16).
A candidate gene study typically involves genotyping 5–50 single nucleotide polymorphisms 
(SNPs) within gene(s) for its coding and non-coding/regulatory regions (17). Irrespective of the 
number of tested gene variants; for a standard conductance, data collection, and transparent 
reporting of a genetic association study, the recommendations of STrengthening the REporting of 
Genetic Association studies (STREGA) and STrengthening the Reporting of OBservational studies 
in Epidemiology (STROBE) should be considered (16). In case-control studies, knowledge of fre-
quency distribution of candidate gene loci/variants among normal (healthy control) population(s) 
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is necessary and could be useful also for genetically related 
population(s) to determine the gene variants associated with 
disease and/or its clinical course.
The role of inflammatory and profibrotic mechanisms involv-
ing gene variation has been investigated in IPF and spectrum of 
susceptible polymorphic gene variants, including those in genes 
of immune reactions and signaling processes, have been recently 
reported from both genome-wide association studies (GWAS) 
and population-based case-control studies (14, 18, 19) performed 
mostly in US Caucasians, and also in some other ethnicities. The 
nominated gene variants, summarized in Table 1, are of different 
functions and implicate some yet-unanticipated pathways in 
IPF pathogenesis, including endoplasmic reticulum stress and 
unfolded protein response, cellular senescence, DNA-damage 
response, and already known Wnt–β-catenin signaling (20). The 
distribution of SNPs may greatly differ with populations (ethnici-
ties), for example, a high frequency of MUC5B rs35705950*T allele 
in IPF cases is observed among European-Americans (14–34%) 
(21, 22), while its low frequency is characteristic for Asians, 
such as Chinese (3.3%) (23), Japanese (3.4%) (24), and Korean 
(1.0%) cohorts (11). Similarly, MUC2 rs7934606*A allele exhibit 
frequency of 41% in Europeans and 1% in Asians (1000 Genomes 
Project Phase 3 allele frequencies). Furthermore, in context of 
taBLe 1 | List of candidate SNps investigated in the study.
S.No. Location Gene SNp ID position Region Functional category Reference
1 2q14.1 IL-1 α rs1800587 112,785,383 5′-flanking region Pro-inflammatory cytokine (25)
2 2q14.1 IL-1 β rs16944 112,837,290 Promoter Pro-inflammatory cytokine (25)
3 2q14.1 IL-1 β rs1143634 112,832,813 Exon (dS) Pro-inflammatory cytokine (25)
4 2p21 PRKCE rs628877 45,698,441 Intron Cellular signaling pathways –
5 3q26 LRRC34 rs6793295 169,800,667 Exon (dN) Protein-protein interaction (26)
6 3q22.1 TF rs1799899 133,756,968 Exon (dN) Iron ion transport –
7 4q13.3 IL-8 rs4073 73,740,307 Promoter Pro-inflammatory cytokine (18)
8 4q22.1 FAM13A rs2609255 88,890,044 Intron GTPase activator activity (26)
9 4q35 TLR3 rs3775291 186,082,920 Exon (dN) Innate immunity (14)
10 5p15 TERT rs2736100 1,286,401 Intron 2 Telomerase maintenance (26)
11 5q31.1 IL-13 rs1800925 132,657,117 Promoter Pro-inflammatory cytokine (27)
12 5q31.1 IL-4 rs2243248 132,672,952 Promoter Pro-inflammatory cytokine (19)
13 5q31.1 IL-4 rs2243250 132,673,462 Promoter Pro-inflammatory cytokine (19)
14 5q31.1 IL-4 rs2070874 132,674,018 Promoter Pro-inflammatory cytokine (19)
15 6p21.2 CDKN1A rs2395655 36,677,919 Promoter Cell cycle regulation (19)
16 6p21.2 CDKN1A rs733590 36,677,426 Promoter Cell cycle regulation (19)
17 6p24 DSP rs2076295 7,562,999 Intron Binds intermediate filaments (26)
18 10q24 OBFC1 rs11191865 103,913,084 Intron Telomerase maintenance (26)
19 11p15.5 MUC2 rs7934606 1,100,037 Intron Mucus production in lungs (26)
20 11p15.5 MUC5B rs35705950 1,219,991 Promoter Mucus production in lungs (12, 21)
21 11p15.5 TOLLIP rs5743890 1,304,599 Intron Innate immunity (21)
22 13q34 ATP11A rs1278769 112,882,313 3′ UTR Phospholipid translocation (26)
23 16p12.1 IL-4R α rs1801275 27,363,079 Exon (dN) Pro-inflammatory cytokines (19)
24 17p13.1 TP53 rs12951053 7,674,089 Intron Cell cycle regulation (28)
25 17p13.1 TP53 rs12602273 7,679,695 Intron Cell cycle regulation (28)
26 17q21 MAPT rs1981997 45,979,401 Intron Microtubule-associated tau (26)
27 17q23.3 ACE rs4277405 63,471,557 Promoter Fibrotic pathway (29)
28 17q23.3 ACE rs4459609 63,471,587 Promoter Fibrotic pathway (29)
29 19p13 DPP9 rs12610495 4,717,660 Intron Serine protease encoding (26)
ACE, angiotensin-converting enzyme; ATP11A, ATPase, class VI, type 11A; AZGP1, alpha-2-glycoprotein 1, zinc-binding; CDKN1A, cyclin-dependent kinase inhibitor 1A, the 
gene encoding p21; COMP, cartilage oligomeric matrix protein; DPP9, dipeptidyl-peptidase 9; DSP, desmoplakin; FAM13A, family with sequence similarity 13, member A; 
IL-13, interleukin-13; IL-8, interleukin-18; LRRC34, leucine rich repeat containing 34; MAPT, microtubule-associated protein tau; MUC2, mucin 2; MUC5B, mucin 5B; OBFC1, 
oligonucleotide/oligosaccharide-binding fold containing 1; PKCE, protein kinase C, epsilon); SFTP, surfactant protein; SPPL2C, signal peptide peptidase like 2C; TERT, telomerase 
reverse transcriptase; TF, transferrin); TGF-β, transforming growth factor-β); TNF-a, tumor necrosis factor-α); TLR3, Toll-like receptor; TOLLIP, toll interacting protein; TP53, tumor 
protein 53; ds, synonymous mutation; dN, non-synonymous mutation; UTR, untranslated region.
participation of more than one gene in IPF pathogenesis, it will 
be important to analyze multiple susceptible gene variants. The 
approach of analyzing common and rare genetic factors in IPF 
susceptibility may provide novel insights into IPF and it could 
also be helpful in identifying population-specific rare variants, 
predominant panel of candidate gene variants for IPF risk and in 
understanding the basis of variable disease severity or progres-
sion among different populations.
No complex data have been yet reported on IPF-related 
variants in Slavonic populations, including Czechs. Starting 
our investigations of plausible multiple IPF susceptibility poly-
morphisms primarily in Czech and also related populations, we 
adopted allele-specific MALDI-TOF mass spectrometry-based 
SNPs genotyping assay for determination of gene variation in 
the relevant targets. Several IPF susceptible SNPs in genes of 
various functional categories were multiplexed, and in the first 
phase genotyped in probands from normal (healthy) Czech 
population using Sequenom MassARRAY platform. In the 
current dataset manuscript, we, besides genotyping methodol-
ogy, report the genotype, allele, and phenotype (carriage rate) 
frequencies for plausible IPF susceptibility variants among 
normal population of Czech Republic of Western Slavonic 
(Caucasian) ancestry.
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Materials and Methods
Characteristics of the Study Group
Ninety-six unrelated healthy subjects (45 males, 51 females), 
free of any disease as assessed by physician’s enquiry about 
their personal and family history, were enrolled. The mean 
age ±standard deviation was 34.5 ± 8.9 years and ranged from 
18–57 years. All were Caucasians, and as assessed by surname and 
tracking personal history of Czech (Western Slavonic) ancestry 
living in Moravian region of the Czech Republic. All probands 
were informed about the purpose of the study and provided 
informed consent; the study was realized with the approval of the 
institutional ethics committee. Genomic DNA was isolated from 
peripheral blood leukocytes by standard salting out method (30).
A list of reference single nucleotide polymorphism database 
ID (rsSNP) was prepared for IPF-associated gene variants identi-
fied from available literature (GWAS and case-control studies) 
(Table 1). SNP genotyping using Sequenom iPLEX and MALDI-
TOF-based MassARRAY platform allows analysis of upto 40 
SNPs in a single well reaction. Primers were designed using 
Assay Design Suite v2.0 (ADS v 2.0) available under online tools 
of Agena Bioscience (https://www.mysequenom.com/Tools).
assay Design, pCR amplification, and 
Genotyping
For online genotyping assay design of multiplexed SNPs using 
ADS v2.0, an input list of SNP IDs (rsSNP of each target) was 
provided and following steps were followed: (1) the sequence for 
each rsSNP was retrieved from database and formatted accord-
ingly, (2) the proximal SNPs for each rsSNP were identified from 
database, and (3) optimal primer areas were identified that result 
in a unique amplicons containing a target for the extension 
primer. To avoid extension primer rejection due to insufficient 
known bases, the proximal base was replaced with inosine. (4) 
PCR and extension primers were designed and checked for false 
priming, hairpin/dimer formation. The primer multiplexes with 
mass separation of analytes (alleles) were created. The PCR primer 
plex was prepared for PCR amplification, and extension primer 
mix was prepared for single base extension (SBE)-based iPLEX 
reaction. The SBE pool plex consists of multiplexed primers that 
anneal adjacent to polymorphic site for each reaction present 
together in the multiplexed assay pool. Thus, several individual 
DNA polymorphisms with their corresponding SNP sites could 
be analyzed in a single reaction. Due to the inverse relationship 
between peak intensity and extend primer mass, the extension 
primers in iPLEX assays were adjusted for concentration to 
ensure the possible equal intensity of extension primers.
For multiplexed PCR amplification and genotyping assay, 
protocol described in literature was followed (31). In brief, 
multiplexed PCR amplification was performed using 10 ng DNA 
template. A cleanup reaction for amplicons plex was performed 
with shrimp alkaline phosphatase (SAP) mix. These SAP cleaned 
amplicons plex were further subjected to SBE reaction with iPLEX 
mix containing extend primer plex. The iPLEX reaction products 
were treated with a cationic resin (SpectroCLEAN, Sequenom) 
to remove salts, such as Na+, K+, and Mg2+ ions. The desalted 
iPLEX extend amplicons were dispensed on SpectroCHIPs using 
MassARRAY® Nanodispenser RS 1000 station and analyzed on 
matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF MS)-based MassARRAY analyzer 
for target allele(s). As assay control of SNP genotyping, a dupli-
cate, positive, and negative control samples were included in each 
assay plate. In each assay, the specific ddNTP incorporated at 
target site could be identified with peak representing increase in 
mass of extend primer. The assay peak spectrum and call cluster 
plot resulting from MALDI-TOF MS analysis were analyzed with 
MassARRAY Typer 4.0.20 software that traces primer masses to 
the assayed alleles.
Statistical analysis
Each SNP was tested for Hardy–Weinberg Equilibrium (HWE) 
by Pearson’s goodness-of-fit, Chi-square (χ2) test. SNPs within 
HWE (p  >  0.05) and sufficiently common (Minor Allele 
Frequency, MAF > 5%) in the general population were included. 
Phenotype frequency (carriage rate) was calculated as proportion 
of individuals carrying one or two copies of a particular allele on 
one or both (maternal or paternal) chromosomes.
Results
Using online Assay Design Suite v2.0 for primer designing, two 
plexes were generated. Plexes I and II consisted of 22 and 7 SNPs, 
respectively. For a successful assay, inosine was used instead of 
proximal SNP in the extend primer sequence for rs2736100, 
rs2243250, and rs4277405 of plex I.
In assay control of multiplexed SNP genotyping, SNP rs2395655 
in CDKN1A showed low assay-success rate (< 95%) and two SNPs 
DSP rs2076295 and TOLLIP rs5743890 were found as positive in 
no template control. These SNPs failed the quality control assess-
ments and were removed from further analysis (Table  2). The 
genotyping assays success rates for all other analyzed SNPs were 
98–100%. In our Czech healthy control population, all analyzed 
SNPs were in HWE, except for IL-4Rα rs1801275 that exhibited 
minor deviation (p =  0.04) reflecting a small anomaly, so the 
locus was not excluded from analysis (Table 2).
Among analyzed SNPs in cytokines, their receptor and sub-
units, IL-4 rs2243248 exhibited highest genotype (TT = 0.85), 
allele frequency (T = 0.93) and carriage rate (T = 1.00). Besides 
cytokines, we also report allelic frequency of rs3775291 in 
TLR3, an innate immune system receptor. In present report, 
four out of 26 SNPs, viz., TP53 rs12951053, TP53 rs12602273, 
TF rs1799899, and IL-4 rs2243248 showed complete absence of 
their respective homozygous genotype CC, GG, AA, and GG, 
and exhibited high phenotype frequency (1.00) for allele A, C, 
G, and T, respectively (Table 2). For MUC5B rs35705950*T risk-
allele, allelic and phenotype frequencies were found as 9% and 
17%, respectively.
The genotype frequency and allele frequency for the 26 ana-
lyzed SNPs are available online at ALlele FREquency Database 
with Sample UID: SA004336Q (http://alfred.med.yale.edu/
alfred/pophetgraph.asp?sampleuid=SA004336Q&cutoff=0.25) 
and will be publicly available at dbSNP database with the release 
of dbSNP Build (B144) (http://www.ncbi.nlm.nih.gov/SNP/
snp_viewTable.cgi?handle=LIGP).
taBLe 2 | Genotype distribution and phenotype frequency of candidate SNps in normal Czech population.
S.No. Genetic variant assay rate (%) Genotype n = 96 HWe allele phenotype frequency
1 IL-1 α
rs1800587
100 CC
CT
TT
39
45
12
0.86 C
T
0.88
0.59
2 IL-1 β
rs16944
100 GG
GA
AA
46
38
12
0.35 G
A
0.88
0.52
3 IL-1 β
rs1143634
100 CC
CT
TT
56
33
7
0.49 C
T
0.93
0.42
4 PRKCE
rs628877
99a GG
GT
TT
61
27
7
0.11 G
T
0.93
0.36
5 LRRC34
rs6793295
100 TT
TC
CC
45
45
6
0.23 T
C
0.94
0.53
6 TF
rs1799899
100 GG
GA
AA
81
15
0
0.41 G
A
1.00
0.16
7 IL-8
rs4073
100 AA
AT
TT
19
51
26
0.50 A
T
0.73
0.80
8 FAM13A
rs2609255
100 TT
GT
GG
53
37
6
0.89 T
G
0.94
0.45
9 TLR3
rs3775291
100 GG
GA
AA
41
44
11
0.88 G
A
0.89
0.57
10 TERT
rs2736100
100 TT
GT
GG
29
48
19
0.91 T
G
0.80
0.70
11 IL-13
rs1800925
100 CC
CT
TT
49
38
9
0.68 C
T
0.91
0.49
12 IL-4
rs2243248
98b TT
GT
GG
80
14
0
0.44 T
G
1.00
0.15
13 IL-4
rs2243250
98b CC
CT
TT
64
25
5
0.24 C
T
0.95
0.32
14 IL-4
rs2070874
100 CC
CT
TT
66
27
3
0.91 C
T
0.97
0.31
15 CDKN1A
rs733590
100 TT
CT
CC
36
47
13
0.71 T
C
0.86
0.63
16 OBFC1
rs11191865
100 GG
AG
AA
33
45
18
0.70 G
A
0.81
0.66
17 MUC2
rs7934606
100 GG
AG
AA
41
48
7
0.16 G
A
0.93
0.57
18 MUC5B
rs35705950
100 GG
GT
TT
80
14
2
0.16 G
T
0.98
0.17
(Continued)
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S.No. Genetic variant assay rate (%) Genotype n = 96 HWe allele phenotype frequency
19 ATP11A
rs1278769
100 GG
GA
AA
48
39
9
0.79 G
A
0.91
0.50
20 IL-4R α
rs1801275
100 AA
AG
GG
68
22
6
0.04 A
G
0.94
0.29
21 TP53
rs12951053
100 AA
CA
CC
81
15
0
0.41 A
C
1.00
0.16
22 TP53
rs12602273
100 CC
GC
GG
81
15
0
0.41 C
G
1.00
0.16
23 MAPT
rs1981997
100 GG
GA
AA
67
26
3
0.81 G
A
0.97
0.30
24 ACE
rs4277405
100 TT
CT
CC
36
48
12
0.51 T
C
0.88
0.63
25 ACE
rs4459609
100 AA
CA
CC
37
46
13
0.83 A
C
0.86
0.61
26 DPP9
rs12610495
100 AA
GA
GG
54
35
7
0.69 A
G
0.93
0.44
aOne sample for PRKCE rs628877.
bTwo samples each for IL-4 rs2243250 and IL-4 rs2243248 were not genotyped.
HWE, Hardy–Weinberg equilibrium.
taBLe 2 | Continued
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Discussion
The present dataset reports the genotype distribution, genotype, 
allele, and phenotype frequency of 26 gene variants involved 
in immune-related pathomechanisms of IPF in normal Czech 
population using Sequenom MassARRAY based genotyping plat-
form. Besides the relevance to the delineation of immunogenetic 
component of IPF, the knowledge of frequency distribution of 
gene variants in normal populations is of considerable impor-
tance for their evaluation as genetic markers in susceptibility, 
manifestation, prognosis, and potentially treatment of diseases 
in different populations (32).
A SNP rs35705950 in the putative promoter of MUC5B 
has been shown to exhibit strong association with both 
familial interstitial pneumonia and IPF (33). The observed 
rs35705950*T risk-allele frequency of 9% in normal Czech 
population was in concordance with other reports in normal 
Caucasians of European-American descents, as 9–11% in 
American (33), 10% in UK Caucasians (34), 11% in French 
(22), and 4.3% in Germans (24) populations among Europeans. 
Interestingly, the MUC5B promoter polymorphism is observed 
less frequently in normal Asian populations, such as 0.8% in 
Japanese (24), 0.7% in Chinese (23), and <1% in Koreans (11). 
Overall, mucin glycoprotein encoding MUC5B has role in nor-
mal lung function by regulating immune function, microbial 
population, airway infection, and mucociliary clearance in 
lungs (35, 36).
Among analyzed cytokines, IL-4 has significant role in 
IPF pathogenesis by regulating fibroblast functions, such as 
chemotaxis, proliferation, collagen synthesis, myofibroblast 
differentiation, and Th1/Th2 equilibrium (19). The angiogenic 
IL-8 was shown as predictive for early stage of IPF (37) and as 
poor IPF survival (38). Additionally, IL-13 and IL-13 pathway 
markers (39) and the innate immune signaling receptor TLR3 
have been suggested as potential markers of rapidly progressive 
form of IPF. Several recent studies have suggested that defective 
TLRs are linked to dysregulated fibrogenesis and have key role 
in myofibroblast activation, increased profibrotic cytokines, 
collagen deposition, fibrosis, and tissue destruction and, thus, 
promoting the progression of disease during the later phase of 
IPF (14, 15, 40, 41).
Of the four variants that exhibited absence of homozygous 
genotypes in this data report: (1) the frequency of TP53 
rs12951053 CC genotype has been reported as 6% in Caucasian 
HC (28), 1.2% in European and Africans and relatively higher in 
Asian (11.9% in Han Chinese and 11.6% in Japanese) populations 
(http://snp-nexus.org/temp/snpnexus_10220/results.html); (2) 
For TP53 rs12602273, CC genotype frequency has been reported 
as 3% in Caucasian healthy controls (28); (3) For TF rs1799899, 
AA genotype frequency has been reported as 0.6% in European, 
and 0.0% among African, Han Chinese, and Japanese popula-
tions (http://snp-nexus.org/temp/snpnexus_10168/results.html); 
and (4) For IL-4 rs2243248, low GG genotype frequency (IL-4, 
-1098 G/T) has been reported in another independent study for 
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